Apply to trial NCT07181837

A few quick questions so the study team can decide if you might be a fit.

RecruitingGenetic intervention

A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome

The purpose of this study is to evaluate the safety and efficacy of MVX-220 gene therapy in children and adults with Angelman syndrome with UBE3A gene deletion, uniparental disomy, or imprinting center defect genotypes.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening